Private Access: Wegovy vs Mounjaro Comparison Guide
What's Better Wegovy or Mounjaro: Private vs NHS Route
When comparing what's better between Wegovy or Mounjaro, the private prescription route offers significant advantages over NHS pathways. The NHS requires GP referral to specialist weight management services, often involving 6+ month waiting lists and strict eligibility criteria that many suitable candidates don't meet. Private prescription eliminates these barriers entirely. Our 3-minute clinical assessment connects you directly with qualified prescribers who can evaluate both Wegovy and Mounjaro options based on your individual circumstances, without lengthy delays or complex referral processes.
This streamlined approach means you can access the same genuine Novo Nordisk Wegovy or Eli Lilly Mounjaro supplied to NHS services, but through a faster, more convenient pathway. Both medications are prescription-only medicines requiring proper clinical oversight, which our GPhC-registered pharmacy (#9012878) provides alongside rapid access. The private route also offers flexible dosing schedules and personalised support that busy NHS services often cannot accommodate.
Wegovy vs Mounjaro Pricing: Transparent Private Costs
Understanding what's better between Wegovy or Mounjaro includes comparing the financial investment required. Wegovy pricing starts at £79.99 for the 0.25mg starter dose, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. New customers apply discount code FIRST40 at checkout to reach these final prices, while returning customers use DOSE25. Our bundle options like the Intro Duo (0.25mg & 0.5mg) at £169.99 provide convenient multi-pen packages for uninterrupted treatment progression.
Mounjaro follows a different pricing structure due to its dual GIP/GLP-1 mechanism, though both medications represent significant private healthcare investments. The key advantage of private prescription isn't just speed — it's the ability to switch between treatments if your prescriber determines one isn't optimal for your response pattern. NHS patients often face months-long waits to change medications, while private patients can adjust their treatment approach more responsively based on tolerability and effectiveness patterns.
Clinical Evidence: What's Better Wegovy or Mounjaro Research
When evaluating what's better between Wegovy or Mounjaro, both demonstrate substantial clinical evidence through different trial programmes. Wegovy's STEP trials showed patients achieved approximately 15% average weight loss at 68 weeks when combined with reduced-calorie diet and increased physical activity, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The STEP programme also demonstrated sustained benefits, with STEP 5 maintaining 15.2% weight reduction over 2 years of treatment.
Mounjaro's clinical programme focused on its dual-hormone approach, targeting both GIP and GLP-1 receptors simultaneously. However, directly comparing percentage outcomes between trials isn't clinically meaningful due to different study populations, endpoints, and methodologies. Both medications require prescription-only access and clinical monitoring, which our experienced prescribers provide through comprehensive assessment and ongoing support throughout your treatment journey.
How Wegovy Works: GLP-1 Mechanism for Weight Management
Understanding what's better between Wegovy or Mounjaro requires grasping their different mechanisms of action. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics glucagon-like peptide-1, a natural hormone released by intestinal cells after eating. This hormone signals satiety to brain appetite centres, promoting feelings of fullness after smaller meal portions and potentially reducing food cravings between meals. The once-weekly injection delivers consistent hormone levels, supporting sustained appetite regulation throughout the week. Unlike rapid-acting appetite suppressants, Wegovy's mechanism works gradually to recalibrate hunger and satiety signals, supporting long-term dietary changes rather than short-term restriction.
Private Prescription Ordering Process: Streamlined Access
Accessing either medication through our private service eliminates traditional healthcare bottlenecks that delay treatment initiation. Our 3-minute online clinical assessment captures essential medical history, current medications, weight management goals, and lifestyle factors that inform prescriber decisions about what's better between Wegovy or Mounjaro for your situation. Qualified prescribers review applications within 3 working days (24 hours for express service), evaluating suitability for either treatment based on MHRA licensing criteria and clinical best practices. Once approved, next-day delivery ensures rapid treatment commencement through temperature-controlled, cold-chain logistics that maintain medication integrity. This process typically takes 4-5 days total compared to months through NHS referral pathways, allowing you to begin your weight management journey without unnecessary delays.
Storage and Practical Considerations: Wegovy vs Mounjaro
Practical differences between treatments can influence what's better between Wegovy or Mounjaro for your lifestyle. Wegovy offers superior storage flexibility, remaining stable for 6 weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day limit. This advantage benefits frequent travellers or those with unreliable refrigeration access. Both use pre-filled injection pens with different designs — Wegovy's FlexTouch pen from Novo Nordisk versus Mounjaro's KwikPen system. Dosing schedules also differ: Wegovy follows a structured 20-week escalation (0.25mg to 2.4mg maintenance), while Mounjaro uses its own progression pattern. Your prescriber will explain proper injection technique, rotation sites, and dose timing to optimise treatment outcomes while minimising potential side effects through gradual introduction.
What's Better Wegovy or Mounjaro: Personalised Treatment Selection
The question of what's better between Wegovy or Mounjaro doesn't have a universal answer — it depends entirely on individual medical history, treatment goals, and response patterns. Some patients respond optimally to Wegovy's single-hormone GLP-1 approach, while others may benefit from Mounjaro's dual GIP/GLP-1 mechanism. Factors like diabetes status, cardiovascular risk, gastrointestinal sensitivity, and previous weight management attempts all influence prescriber recommendations.
Private prescription allows for more personalised treatment selection compared to standardised NHS protocols. If your initial choice proves suboptimal due to side effects or insufficient response, switching between medications becomes feasible without lengthy re-referral processes. This flexibility represents a key advantage of private care — your treatment can evolve based on real-world response rather than being locked into rigid healthcare pathways that prioritise system efficiency over individual optimisation.
Start Your Weight Management Journey Today
Rather than debating what's better between Wegovy or Mounjaro indefinitely, take action through our comprehensive private prescription service. Both treatments are available with transparent pricing, rapid access, and expert prescriber guidance to determine your optimal choice. New customers save with code FIRST40, while returning customers use DOSE25, applied automatically at checkout to reach our competitive final prices. Our GPhC-registered pharmacy (#9012878) ensures you receive genuine, pharmaceutical-grade medications with proper cold-chain handling and next-day delivery. Complete your 3-minute assessment today at https://everydaymeds.co.uk/collections/wegovy to begin your professionally-supported weight management journey without delay. Your prescriber will evaluate both options and recommend the treatment most likely to support your individual goals alongside a reduced-calorie diet and increased physical activity.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
